Characterization of pathogen‐inactivated <scp>COVID</scp> ‐19 convalescent plasma and responses in transfused patients-Reference-Cited by-同舟云学术

Characterization of pathogen‐inactivated COVID ‐19 convalescent plasma and responses in transfused patients

Published:2022-09-05 Issue:10 Volume:62 Page:1997-2011
ISSN:0041-1132
Container-title:Transfusion
language:en
Short-container-title:Transfusion

Author:

Weisser Maja¹²^ORCID,Khanna Nina¹²,Hedstueck Anemone¹,Sutter Sarah Tschudin¹²,Roesch Sandra¹,Stehle Gregor³,Sava Mihaela¹,Deigendesch Nikolaus⁴,Battegay Manuel¹²,Infanti Laura³,Holbro Andreas³,Bassetti Stefano²⁵,Pargger Hans²⁶,Hirsch Hans H.¹²⁷,Leuzinger Karoline⁷,Kaiser Laurent⁸⁹,Vu Diem‐Lan¹⁰,Baur Katharina³,Massaro Nadine³,Busch Michael Paul¹¹¹²,Simmons Graham¹¹¹²,Stone Mars¹¹¹²,Felgner Philip L.¹³,de Assis Rafael R.¹³,Khan Saahir¹⁴,Tsai Cheng‐ting¹⁵,Robinson Peter V.¹⁵,Seftel David¹⁵,Irsch Johannes¹⁶,Bagri Anil¹⁶,Buser Andreas S.²³^ORCID,Corash Laurence¹⁶^ORCID

Affiliation:

1. Division of Infectious Diseases & Hospital Epidemiology University Hospital of Basel Basel Switzerland

2. Department of Clinical Research University Hospital Basel Basel Switzerland

3. Regional Blood Transfusion Service Swiss Red Cross Basel Switzerland

4. Institute of Pathology University Hospital Basel Basel Switzerland

5. Department of Internal Medicine University Hospital Basel Basel Switzerland

6. Department of Intensive Care University Hospital Basel Basel Switzerland

7. Transplantation & Clinical Virology, Department of Biomedicine University of Basel Basel Switzerland

8. Geneva Centre for Emerging Viral Diseases Geneva University Hospitals Geneva Switzerland

9. Laboratory of Virology, Division of Laboratory Medicine Geneva University Hospitals & Faculty of Medicine, University of Geneva Geneva Switzerland

10. Division of Infectious Diseases Geneva University Hospitals Geneva Switzerland

11. Department of Laboratory Medicine University of California San Francisco California USA

12. Vitalant Research Institute San Francisco California USA

13. Department of Physiology and Biophysics, Vaccine Research and Development Laboratory University of California Irvine California USA

14. Division of Infectious Diseases, Department of Medicine, Keck School of Medicine University of Southern California Los Angeles California USA

15. Enable Biosciences Inc. South San Francisco California USA

16. Cerus Corporation Concord California USA

Publisher

Wiley

Subject

Hematology,Immunology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/trf.17083

Reference86 articles.

1. CenterJHCR.Johns Hopkins coronavirus resource Center 2021‐06‐04 2021. Accessed 2021‐06‐04.

2. Compassionate Use of Remdesivir for Patients with Severe Covid-19

3. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

4. Remdesivir for the Treatment of Covid-19 — Final Report

5. Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mortality Rates Among Hospitalized Patients With COVID-19 Treated With Convalescent Plasma: A Systematic Review and Meta-Analysis;Mayo Clinic Proceedings: Innovations, Quality & Outcomes;2023-10

2. Characterization of antibodies to SARS‐CoV‐2 in lyophilized plasma prepared with amotosalen‐UVA pathogen reduction;Transfusion;2023-08-24

3. The Impact of Pathogen Reduction on Total IgG and IgG Subclass Profiles of Convalescent Plasma;Transfusion Medicine and Hemotherapy;2023-06-21

4. Studien-Kommentar;Transfusionsmedizin;2023-02

5. COVID-19: Transfusion mit pathogeninaktiviertem Rekonvaleszenten-Plasma;Transfusionsmedizin;2023-02